Organisation paid for research Program year 2025 Source: CMS Open Payments

Clinrx Research Joseph Inc

Neither a doctor nor a teaching hospital

Research payments

$885,220

129 payments

Through program year 2025, Clinrx Research Joseph Inc is reported as receiving $885,220 in research payments, across 129 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $130,152 19
2024 Research $212,679 46
2023 Research $60,800 21
2022 Research $31,060 7
2021 Research $21,784 6
2020 Research $91,659 23
2019 Research $337,086 7

Breakdown

Who paid Research payments · program years 2019–2025
  1. Sanofi US Services Inc. $380,227 60 payments
  2. AstraZeneca Pharmaceuticals LP $358,731 11 payments
  3. Allergan Inc. $75,132 24 payments
  4. Chiesi USA, Inc. $67,084 33 payments
  5. Amgen Inc. $4,046 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) $271,007 29 payments
  2. Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos) $193,369 2 payments
  3. A Randomized Double-Blind Parallel Group Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva Respimat in Subjects With Persistent Asthma $160,243 4 payments
  4. A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation $75,075 24 payments
  5. A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. $49,384 30 payments
  6. A 54-Week Treatment, Multicenter, Randomized, Double-Blind, Double- Dummy, Placebo and Active-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy and Safety of Brazikumab in Participants with Moderately to Severely Active Ulcerative Colitis $44,003 14 payments
  7. A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies $34,144 7 payments
  8. A 52-Week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo and Active-Controlled, Operationally Seamless Phase 2b/3, Parallel-group Study to Assess the Efficacy and Safety of Brazikumab in Participants with moderately to Severely Active Croh $28,259 9 payments
  9. A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp 500g) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) (PILLAR) $11,000 1 payment
  10. A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. $6,700 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record